Literature DB >> 28413674

Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.

Naomi Serling-Boyd1, Zoe Quandt2, Nazima Allaudeen3.   

Abstract

Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, with most cases occurring in hematological malignancies following the initiation of treatment. However, on rare occasions, TLS may occur in solid tumors as well. In the present case study, the case is reported of a 56-year-old African-American man who presented with a recent diagnosis of prostate cancer, abdominal pain, elevated transaminases, renal insufficiency, hyperkalemia, and hyperuricemia, consistent with spontaneous TLS in the setting of metastatic prostate cancer. A computed tomography scan of the patient's abdomen demonstrated diffuse metastatic tumor burden. Following treatment with allopurinol, rasburicase, and initiation of anti-androgen therapy for the prostate cancer, the patient's TLS laboratory results normalized, however, his renal functions continued to decline. TLS is rare in solid tumors, and particularly rare in prostate cancer, with only six other case reports of the syndrome occurring to the best of our knowledge. This case report highlights the need for early recognition of TLS, even in cases that are not typically associated with the syndrome, as prompt diagnosis will affect early management and may be able to prevent or minimize complications.

Entities:  

Keywords:  hyperuricemia; metastatic prostate cancer; spontaneous tumor lysis syndrome

Year:  2017        PMID: 28413674      PMCID: PMC5374943          DOI: 10.3892/mco.2017.1186

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  11 in total

1.  Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.

Authors:  Cheng-Jui Lin; Ruey-Kuen Hsieh; Ken-Hong Lim; Han-Hsiang Chen; Yi-Chou Cheng; Chih-Jen Wu
Journal:  South Med J       Date:  2007-09       Impact factor: 0.954

2.  Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer.

Authors:  Sandra Mazzoni
Journal:  Int Urol Nephrol       Date:  2016-07-14       Impact factor: 2.370

Review 3.  Onco-nephrology: tumor lysis syndrome.

Authors:  F Perry Wilson; Jeffrey S Berns
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

4.  Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.

Authors:  Jonathan L Wright; Daniel W Lin; Puneet Dewan; R Bruce Montgomery
Journal:  Int J Urol       Date:  2005-11       Impact factor: 3.369

Review 5.  Tumour lysis syndrome: new therapeutic strategies and classification.

Authors:  Mitchell S Cairo; Michael Bishop
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

Review 6.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer.

Authors:  Steven M Sorscher
Journal:  Cancer Chemother Pharmacol       Date:  2004-05-18       Impact factor: 3.333

8.  Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?

Authors:  Eleonora Vaisban; Andrei Braester; Ofri Mosenzon; Maya Kolin; Yvona Horn
Journal:  Am J Med Sci       Date:  2003-01       Impact factor: 2.378

Review 9.  Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Maliha Khan; Aram Barbaryan
Journal:  Rare Tumors       Date:  2014-06-13

10.  Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis.

Authors:  Muhammet Ali Kaplan; Mehmet Kucukoner; Gulistan Alpagat; Abdurrahman Isikdogan
Journal:  Ann Saudi Med       Date:  2012 May-Jun       Impact factor: 1.526

View more
  4 in total

1.  Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report.

Authors:  Masashi Oshima; Shozaburou Mayumi; Kai Yazaki; Yuuki Nakamura; Tsuzumi Konishi; Kimitoshi Saito; Satoshi Washino; Tomoaki Miyagawa
Journal:  IJU Case Rep       Date:  2019-04-15

2.  Spontaneous Tumor Lysis Syndrome in a Patient with a Dedifferentiated Endometrial Adenocarcinoma.

Authors:  Shinichi Harada; Keiki Nagaharu; Youichirou Baba; Tetsuya Murata; Toshiro Mizuno; Keiki Kawakami
Journal:  Case Rep Oncol Med       Date:  2017-08-27

Review 3.  Intricate Interplay of Entwined Metabolic and Inflammatory Life-threatening Processes in Tumor Lysis Syndrome Complicating Prostate Cancer: A Systematic Review with a Single Institution Experience.

Authors:  Dawood Findakly; Jue Wang
Journal:  Cureus       Date:  2020-03-24

4.  Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer.

Authors:  Sidra Javed
Journal:  Curr Oncol       Date:  2021-01-13       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.